Mohit Bansal
Stock Analyst at Wells Fargo
(4.02)
# 566
Out of 4,918 analysts
163
Total ratings
59.14%
Success rate
9.17%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Equal-Weight | $97 → $90 | $79.29 | +13.51% | 11 | Jul 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Downgrades: Equal-Weight | $700 → $580 | $558.87 | +3.78% | 18 | May 30, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $50 → $47 | $30.48 | +54.20% | 2 | May 13, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $60 → $65 | $59.02 | +10.13% | 7 | May 7, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $62 → $53 | $44.23 | +19.83% | 9 | Apr 28, 2025 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Equal-Weight | $7 → $1 | $0.77 | +29.58% | 4 | Apr 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $970 → $1,100 | $762.33 | +44.29% | 17 | Mar 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $140 | $113.18 | +23.70% | 11 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $240 | $195.22 | +22.94% | 8 | Mar 5, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $165 → $140 | $131.95 | +6.10% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $130 → $170 | $115.52 | +47.16% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $460 | $462.13 | -0.46% | 10 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $296.88 | -5.69% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $27.08 | +10.80% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $170 | $107.40 | +58.29% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $20.96 | +233.97% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $27 | $15.58 | +73.35% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $58.14 | +54.80% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $23.49 | +27.71% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $128.99 | +31.79% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $13.65 | +97.80% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $9.65 | +19,330.05% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.74 | +4,753.06% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $11.36 | +67.25% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.08 | +6,157.82% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.15 | +5,117.39% | 4 | Dec 3, 2019 |
Merck & Co.
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $97 → $90
Current: $79.29
Upside: +13.51%
Regeneron Pharmaceuticals
May 30, 2025
Downgrades: Equal-Weight
Price Target: $700 → $580
Current: $558.87
Upside: +3.78%
Xenon Pharmaceuticals
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $30.48
Upside: +54.20%
Halozyme Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $59.02
Upside: +10.13%
Bristol-Myers Squibb Company
Apr 28, 2025
Maintains: Equal-Weight
Price Target: $62 → $53
Current: $44.23
Upside: +19.83%
Ironwood Pharmaceuticals
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $0.77
Upside: +29.58%
Eli Lilly and Company
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $762.33
Upside: +44.29%
Gilead Sciences
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $113.18
Upside: +23.70%
AbbVie
Mar 5, 2025
Maintains: Overweight
Price Target: $210 → $240
Current: $195.22
Upside: +22.94%
Biogen
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $131.95
Upside: +6.10%
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $115.52
Upside: +47.16%
Jan 30, 2025
Downgrades: Equal-Weight
Price Target: $460
Current: $462.13
Upside: -0.46%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $296.88
Upside: -5.69%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $27.08
Upside: +10.80%
Dec 11, 2024
Initiates: Overweight
Price Target: $170
Current: $107.40
Upside: +58.29%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $20.96
Upside: +233.97%
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $15.58
Upside: +73.35%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $58.14
Upside: +54.80%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $23.49
Upside: +27.71%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $128.99
Upside: +31.79%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $13.65
Upside: +97.80%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $9.65
Upside: +19,330.05%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $0.74
Upside: +4,753.06%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $11.36
Upside: +67.25%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.08
Upside: +6,157.82%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.15
Upside: +5,117.39%